BioSpace News Archive

XORTX Therapeutics Inc. is pleased to announce new proof of concept data demonstrating, in a second study, the effectiveness of xanthine oxidase inhibition (“XOI”) produced by the Company’s proprietary oral oxypurinol formulation, XORLO TM.

BIOXYTRAN, INC. announced the receipt of an Investigational New Drug (IND) authorization letter from India’s Central Drugs Standard Control Organization (CDSCO) to optimize dosage in Covid-19 patients.

Evogene Ltd. announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement.

QurAlis Corporation today announced the authorization of its clinical trial application (CTA) by Health Canada for QRL-201, a first-in-class STATHMIN-2 (STMN2) precision medicine for ALS.

INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease will present data from UK patients with MDS or AML treated with INKmune™ at the annual American Society for Hematology (ASH) Conference held in New Orleans December 10th – 13th.

Eyenovia, Inc. today announced that Bren Kern, who currently serves as Eyenovia’s Senior Vice President of Manufacturing and Operations, has been promoted to Chief Operating Officer and Corporate Vice President, effective January 1st.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced four data presentations at the American College of Neuropsychopharmacology (ACNP) 61st Annual Meeting highlighting the therapeutic use of CAPLYTA for the treatment of bipolar I and II depression.

MiMedx Group, Inc. today announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform, PermaFusion®, for the development of future biologic products focused on wound and surgical recovery applications.

iCAD, Inc. will be featured in the next “ProFound Insights, ProFound Impact” webinar, on Dec. 14 at 3 pm EST / 12 pm PST.

PathomIQ Inc., today announced the application of an AI-powered tool to predict response to Neoadjuvant Chemotherapy (NAC) in patients with Triple Negative Breast Cancer (TNBC) presented at the San Antonio Breast Cancer Symposium (SABCS), held from December 6-10, 2022.